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Abstract
Hypercholesterolemia is defined as excessively high plasma cholesterol levels, and is a strong risk factor for many
negative cardiovascular events. Total cholesterol levels above 200 mg/dl have repeatedly been correlated as an
independent risk factor for development of peripheral vascular (PVD) and coronary artery disease (CAD), and
considerable attention has been directed toward evaluating mechanisms by which hypercholesterolemia may
impact vascular outcomes; these include both results of direct cholesterol lowering therapies and alternative inter-
ventions for improving vascular function. With specific relevance to the microcirculation, it has been clearly
demonstrated that evolution of hypercholesterolemia is associated with endothelial cell dysfunction, a near-
complete abrogation in vascular nitric oxide bioavailability, elevated oxidant stress, and the creation of a strongly
pro-inflammatory condition; symptoms which can culminate in profound impairments/alterations to vascular
reactivity. Effective interventional treatments can be challenging as certain genetic risk factors simply cannot be
ignored. However, some hypercholesterolemia treatment options that have become widely used, including phar-
maceutical therapies which can decrease circulating cholesterol by preventing either its formation in the liver or its
absorption in the intestine, also have pleiotropic effects with can directly improve peripheral vascular outcomes.
While physical activity is known to decrease PVD/CAD risk factors, including obesity, psychological stress, impaired
glycemic control, and hypertension, this will also increase circulating levels of high density lipoprotein and improv-
ing both cardiac and vascular function. This review will provide an overview of the mechanistic consequences of
the predominant pharmaceutical interventions and chronic exercise to treat hypercholesterolemia through their
impacts on chronic sub-acute inflammation, oxidative stress, and microvascular structure/function relationships.
Introduction
While hypercholesterolemia, defined as excessively high
plasma cholesterol levels, has emerged as a strong risk
factor for cardiovascular disease (CVD). Data acquired
by the National Health and Nutrition Examination Sur-
vey (NHANES) 2005-2006 found that the mean total
serum cholesterol for Americans over the age of 20 was
199 mg/dl, approximating the American Heart Associa-
tion (AHA) recommended level of 200 mg/dl [1].
Unfortunately, 16% of adults were found to have total
cholesterol levels of more than 240 mg/dl, a level con-
sidered by the AHA to carry twice the CVD risk of
those individuals at the desired level [1,2].
Total cholesterol can be broken down into a diagnos-
tic lipoprotein profile, including high density lipoprotein
(HDL), low density lipoprotein (LDL), intermediate den-
sity lipoproteins (IDL), very low density lipoprotein
(VLDL), chylomicron remnants, and triglycerides. With
respect to these markers, the AHA publishes recom-
mendations summarized in Table 1 [1]. HDL is consid-
ered to be beneficial as higher levels have been
correlated with reduced risk of negative cardiovascular
events, in large measure by promoting reverse choles-
terol transport, an anti-atherogenic process resulting in
cholesterol from peripheral tissues returning to the liver
for subsequent processing [1]. Elevated LDL cholesterol
and triglycerides are considered detrimental as their
increased concentration is well correlated with poor car-
diovascular outcomes [1,3]. Ongoing study has also sug-
gested that IDL, VLDL, and chylomicron remnants may
also play an active role in peripheral vascular (PVD) and
coronary artery disease (CAD) development [3].
As high total cholesterol levels are considered to be a
major independent risk factor for development of PVD
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toward evaluating the impact and mechanisms of cho-
lesterol lowering therapies and interventions for cardio-
vascular outcomes [2-4]. Cholesterol has been shown to
interrupt and alter vascular structure and function as it
builds within the lining of the vascular wall, and can
interfere with endothelial function leading to lesions,
plaques, occlusion, and emboli; along with a reduction
in healing, recovery, and appropriate management of
ischemia/reperfusion injury [5-9]. With specific rele-
vance to the microcirculation, it has been clearly
demonstrated that evolution of hypercholesterolemia is
associated with endothelial cell dysfunction [5,10-14].
Additionally, reports have shown a near-complete abro-
gation in vascular nitric oxide (NO) bioavailability,
elevated oxidant stress, and the creation of a strongly
pro-inflammatory condition; symptoms which can cul-
minate in profound impairments to vascular reactivity
[10,12,15-22]. Investigation into vascular consequences
of chronic hypercholesterolemia, the mechanisms
through which these consequences occur, and the
potentially beneficial effects of ameliorative therapies
have received considerable attention in recent years
[3,9,12,15,17,23-26].
Although a substantial risk factor for CVD, hypercho-
lesterolemia has also been demonstrated to be manage-
able, as summarized in meta-analytic projects which have
supported the use of pharmaceutical interventions to
reduce cholesterol, with the outcome of lowering cardio-
vascular event incidence [24,27]. However, effective inter-
ventional treatment can be problematic, as the presence
of specific genetic risk factors are frequently present. The
condition of familial hypercholesterolemia (FH) is an
inherited autosomal dominant disorder caused by varia-
tions to the low density lipoprotein receptor (LDLR)
gene, preventing effective function and dramatically ele-
vating levels of circulating LDL [28]. While the phenoty-
pic effects of the homozygous condition are more severe,
the prevalence of the heterozygous condition affects
approximately 1 in 500 individuals [29]. Normally, LDL
transports cholesterols and fats through the aqueous
bloodstream to the cell surface where LDLR mediates its
endocytosis, a process that is rendered ineffective in FH.
A second inherited cause of hypercholesterolemia is
familial combined hyperlipidemia (FCH), also known as
type III hyperlipidemia, which presents high cholesterol
and high triglyceride levels stemming from a number of
gene polymorphisms [30]. Interestingly, while the dyslipi-
demic profile of these two conditions differs, there is a
striking similarity in the poor vascular outcomes [8,12].
Hypercholesterolemia and Vascular Dysfunction
The vascular endothelium, a single cell layer on the inner
surface of all vessels, is capable of producing numerous
bioactive molecules, thereby acting as an autocrine, para-
crine, and endocrine organ [26]. In a normal system,
endothelial cells maintain vascular tone via endothelium-
derived relaxing factors including NO, prostacyclin, and
endothelium-derived hyperpolarizing factors [14] in an
integrated balance with sympathetic and myogenic tone
as well as parenchymal cell influences. These molecules
help to regulate the homeostasis of the vascular system
by adjusting to a number of systemic demands on blood
flow, coagulation, inflammation, platelet aggregation, and
signal transduction, with any decay in efficacy considered
as dysfunction [31].
Nitric oxide (NO), a gas synthesized from the amino
acid L-arginine through the enzyme nitric oxide synthase
(NOS), has been widely considered as an endothelium-
dependent regulator of vascular tone, with additional
roles in preventing platelet activation, inhibiting oxidative
stress, cell growth, and inflammation, among others
[16,32]. Asymmetric dimethylarginine (ADMA) is an
endogenous inhibitor of NOS through competition with
L-arginine [22]. Given recent studies demonstrating an
increased endogenous production of ADMA in hyperch-
olesterolemia and the inverse relationship between NO
production and ADMA concentration, ADMA elevations
are currently under intensive evaluation as an additional
risk factor for CVD [20,22].
Previous studies within our laboratory and others have
shown that dilator reactivity in response to NO-depen-
dent stimuli is moderately impaired in hypercholestero-
lemic mice as compared to responses in control animals
Table 1 American Heart Association guidelines for cholesterol and triglycerides levels in adults. Last updated 7/2/09
Total LDL HDL Triglycerides
Optimal - < 100 mg/dL* > 60 mg/dL -
Near optimal/above optimal < 200 mg/dL 100 - 129 mg/dL 40-50 mg/dL (men)
50-60 mg/dL (women)
< 150 mg/dL
Borderline high 200-239 mg/dL 130 - 159 mg/dL - 150-199 mg/dL
High - 160 - 189 mg/dL - 200-499 mg/dL
Very high ≥ 240 mg/dL > 190 mg/dL < 40 mg/dL (men)
< 50 mg/dL (women)
≥ 500 mg/dL
* If the patient has additional risk factors LDL levels are recommended under 70 mg/dL.
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to react to the NO signal, as vessels are able to respond
normally to NO donors, rather there is a reduction in
the bioavailability of NO within vasculature either via
deficits in production or due to increased oxidant
scavenging [13]. Additional data suggests that NO-
mediated endothelium-dependent responses within a
hypercholesterolemic milieu may differ between conduit
vessels and the microcirculation, as peripheral resistance
arterioles have a greater sensitivity to local metabolite
production [38-40]. Further, in hypercholesterolemic
mice and diet induced hypercholesterolemic rabbits,
compensatory mechanisms evolve to maintain endothe-
lium-dependent dilation as a result of a decrease in NO
bioavailability, and appear to involve altered patterns of
arachidonic acid metabolism involving both the cycloox-
ygenase and lipoxygenase pathways [11,12,23,41-43].
Arachidonic acid action within hypercholesterolemia is
not limited to metabolite production inducing dilation,
but includes the production of thromboxane A2 (TXA2),
a potent vasoconstrictor [15,44]. Hypercholesterolemic
animals have shown a limitation to arachidonic acid
induced dilation due to an increase in TXA2 production
during metabolism [15]. Similar hypercholesterolemic
animals have shown an improvement in vascular reactiv-
ity and atherosclerotic lesions in animals who are
thromboxane receptor deficient [15,45,46].
The vascular consequences of lipoprotein remnants
within the hypercholesterolemia, independent of but in
addition to endothelial dysfunction, can lead to organ
dysfunction and subsequently greater systemic conse-
quences due to an impairment of tissue perfusion. This
impairment can be classified as arteriolar remodeling or
capillary rarefaction due to the buildup of cholesterol
within the hyperlipidemic population. Rarefaction may
play a role in many of the systemic effects stemming
from structural pathologies reported within this popula-
tion, including but not limited to changes within the
skin, glomerulopathy leading toward kidney dysfunction
and hypertension, reductions in coronary flow reserve
leading to an early coronary heart disease and hepatic
dysfunction leading toward non-alcoholic fatty liver dis-
ease [47-51].
Hypercholesterolemia and Inflammation
Numerous studies have clearly established that hyperch-
olesterolemia leads to an inflammatory response within
the microvasculature, reflected by endothelial cell activa-
tion, leukocyte recruitment, rolling and adherence, as
well as platelet activation and adhesion characterized in
Figure 1 [18,52]. Platelet activation can initiate leukocyte
recruitment to lesion prone areas as evidenced by an
increased surface CD40 expression indicative of cellular
activation [18,53]. Leukocyte activation can subsequently
obstruct capillary networks, reducing capillary perfusion
- a condition previously identified in hypercholesterole-
mia [19].
The decreased bioavailability of NO in hypercholester-
olemia also diminishes the anti-inflammatory properties
of the endothelial cell, permitting the activity of growth
factors on the cell surface and platelet activation to act
as chemoattractants to a parade of inflammatory events.
Leukocytes begin to roll along the lumen and adhere to
the cell wall, extravasating due to an increase in vascular
permeability, and residing within the intimal space [22].
Monocyte chemotactic protein-1 (MCP-1) and interleu-
kin-8 (IL-8) have both been found to be important in
hypercholesterolemic patients, acting to increase mono-
cyte recruitment and adherence which leads to wall
remodeling [6,54-56]. Macrophages, derived from mono-
cytes, begin to accumulate LDL and oxidized LDL
(oxLDL) which develop into foam cells between the
basal lamina of the endothelium and the smooth muscle
layer [26]. These foam cells lead to the production of
numerous inflammatory and oxidative stress markers,
cytokines, chemokines, and growth factors which aggra-
vate the balance of endothelial equilibrium leading to
vascular dysfunction [57].
Elevated cholesterol has also been shown to trigger
the release of the inflammatory mediator C-reactive pro-
tein (CRP), a useful clinical marker of CVD [58,59]. It is
hypothesized that CRP, via IL-6, may exacerbate vascu-
lar dysfunction by inhibiting eNOS, stimulating produc-
tion of reactive oxygen species and increasing vascular
permeability, and may also initiate the expression and
stimulation of adhesion molecules, chemokine produc-
tion, and thrombus formation within endothelial cells
[54]. Unfortunately, as a cellular marker of vascular
inflammation, the source of CRP within the hypercho-
lesterolemic condition is unclear [60].
Hypercholesterolemia and Oxidative Stress
Excess oxidative stress is caused by an imbalance
between pro- and anti-oxidant enzymes, leading to an
overproduction of free radicals, including superoxide,
hydroxyl radicals, and lipid radicals, which may damage
cellular components, interfering with normal function
again characterized in Figure 1. Other molecules such as
peroxynitrite, hydrogen peroxide, and hypochlorous acid
are also oxidants, but are not free radicals. The two
major sources of oxidants within the vasculature are leu-
kocytes (macrophages) recruited due to an endothelial
injury signal and inefficiencies within smooth muscle
cell mitochondrial metabolism [61].
Hypercholesterolemia may also increase activity of
three major oxidant producing enzyme systems;
NADPH oxidases (NOX), xanthine oxidase, and myelo-
peroxidase. NOX acts to transfer an electron to an
Stapleton et al. Journal of Inflammation 2010, 7:54
http://www.journal-inflammation.com/content/7/1/54
Page 3 of 10oxygen molecule, forming superoxide ultimately H2O2
[62]. While seven NOX isoforms have been identified
(NOX1-5, DUOX 1 and 2), four of these (NOX1, 2, 4,
and 5) have been recognized within the vascular wall,
with NOX2 responsible for the greatest impact on ROS-
related decreases to NO bioavailability [63]. Xanthine
oxidase forms superoxide and H2O2 during the reduc-
tion of oxygen, while myeloperoxidase is produced by
neutrophils and monocytes and produces a toxic hypo-
chlorous acid; within a pathological condition overactive
enzymes can lead to the overproduction these radicals,
leading to scavenging of NO molecules, uncoupling of
eNOS, and/or the formation of peroxynitrite [61]. eNOS
uncoupling and substrate reduction (tetrahydrobiopterin
(BH4) and L-arginine), can transform eNOS into a
superoxide generating enzyme which can, in turn, pro-
duce greater amounts of oxidant radicals and hydrogen
peroxide in addition to NO production [32,64].
A range of antioxidant mechanisms are in place to mini-
mize and balance the effects of ROS, including superoxide
dismutase (SOD), glutathione peroxidase (GPx4), catalase,
and thioredoxin reductase. SOD, which comes in three
forms, soluble cytoplasmic (SOD1), extracellular (SOD3)
containing copper and zinc and mitochondrial (SOD2)
containing manganese, is the main cellular antioxidant
system in all cell types and is capable of converting super-
oxide radicals to H2O2 and oxygen [58,65,65]. GPx4
reduces H2O2 and lipid peroxides to water and lipid alco-
hols, and reduces the development of atherosclerosis dur-
ing hypercholesterolemia through the inhibition of lipid
peroxidation and a decreased sensitivity of endothelial
cells to oxidized lipids [66]. Catalase acts to reduce hydro-
gen peroxide to oxygen molecules and water. Within the
pathological state of hypercholesterolemia, antioxidant
systems are unable to handle the increased demand and
the ROS production exceeds capacity.
Figure 1 Figure illustrates the vascular progression of disease within a hypercholesterolemic environment. The depiction gives a
simplified version of the process, while including documented signaling adaptations associated with hypercholesterolemia, pharmaceutical
therapies, and exercise interventions
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radicals or enzymatic oxidation and lipoproteins or more
specifically phospholipids can lead to production of lipid
radicals (oxLDL) or oxidized phospholipids (OxPL). These
OxPL can interact with membrane receptors to accumu-
late within the cellular membrane, disrupting normal cel-
lular function through a reduced bioavailability of NO,
eliciting an immune response, leading to poor vascular
function, and ultimately atherosclerosis [14,67,68]. This
conclusion is further supported with evidence that choles-
terol fed animals with polyethylene-glycolated-SOD
demonstrate an improved endothelium dependent dila-
tion, while normocholesterolemic animals did not show
any effects [69]. OxPL can interact directly with the
endothelial cell through interactions with the lectin-like
oxLDL receptor (LOX-1), an endothelial receptor for oxi-
dized LDL in endothelial cells; this receptor is induced by
a variety of inflammatory cytokines, oxidative stress,
hemodynamic changes, and abundance of ox-LDL [70]. In
addition to oxLDL, LOX-1 can bind advanced glycation
end products (AGE), activated platelets, and leukocytes all
furthering inflammatory and oxidative processes [70].
Lastly, as the interactions with oxPL cause further injury
subsequently activating the endothelial cell and platelets,
signaling a variety of adhesion and inflammatory mole-
cules including MCP-1, leading to monocyte recruitment,
diapedesis, macrophage differentiation, and foam cell for-
mation only further aggravates the delicate system by pro-
ducing additional ROS and inflammatory recruitment
[68,71].
Hypercholesterolemia and Pharmaceutical
Therapies
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG
CoA) reductase inhibitors, are currently one of the most
widely prescribed drugs on the market. They target liver
HMG CoA reductase activity and inhibit the production of
a cholesterol precursor, mevalonic acid. They also specifi-
cally act to change the conformation of HMG-CoA reduc-
tase when bound, preventing a functional structure [25].
This enzymatic inhibition acts to prevent protease activa-
tion of sterol regulatory element binding proteins (SREBPs)
from the endoplasmic reticulum, thereby preventing
nuclear translocation and upregulation of LDL gene
expression, limiting hepatic cholesterol production [25].
Statins have been identified to have numerous positive
outcomes associated with their direct cholesterol lower-
ing [72-75]. However, in addition to these, vasculoprotec-
tive properties such as increased NO bioavailability,
antioxidant, anti-inflammatory and immunomodulatory
properties leading to an overall improvement of endothe-
lial function have also been identified; yet specifically
identifying the discrete result in human hypercholestero-
lemic patients is difficult as the cholesterol lowering
benefits are similar [76,77]. Additionally, statin therapy
has been found to significantly improve endothelial func-
tion (based on flow-mediated dilator responses) in
hypercholesterolemic patients who had also been diag-
nosed with peripheral artery disease [78]. While this ben-
eficial effect may have resulted from an increased NO
bioavailability, the underlying mechanisms have not been
fully understood [79].
These diverse positive vascular outcomes are most
easily identified while using a genetically modified mur-
ine model, as the lipid-lowering results become null, leav-
ing the pleiotropic effects evident. While similar to the
secondary benefits of direct cholesterol lowering, these
independent effects described include: reducing inflam-
mation, decreases in ROS, increases in NO bioavailability
and endothelial function, decreases in platelet activation
and aggregation, reduction in coagulation and decreases
in cellular proliferation, among others [42]. Unfortu-
nately, at this time while the independent outcomes are
evident, the mechanisms of action leading to these
improvements are not fully elucidated.
Ezetimibe (Zetia) is a selective agent which acts to
prevent cholesterol absorption in the intestine through
targeting Niemann-Pick C1-like 1 protein (NPC1L1),
which is expressed on the intestinal cell surface and is a
transporter with secretion signal and sterol-sensing
domains. Ezetimibe will inhibit this protein, thereby
blocking LDL uptake from the intestine [80]. The subse-
quent reduction in cholesterol transport to the liver sti-
mulates a compensatory increase in LDLR expression,
thereby increasing vascular clearance with no known
serious side effects [9]. While cholesterol lowering thera-
pies have shown a positive correlation with reductions
in cardiovascular events, ezetimibe has recently begun
to show pleiotropic effects such as reductions in liver
lipids, reductions in lipid lesions, reductions in ADMA
levels, and increases in eNOS mRNA expression [26,75].
When used in combination, ezetimibe and statins (e.g.,
Vytorin) act via complementary pathways to prevent cho-
lesterol absorption from the intestine and hepatic produc-
tion. Long term co-administration of these drugs have
been shown to reduce LDL blood cholesterol levels by 60%
while concurrently raising HDL levels and limiting liver
toxicity, myotoxicity and/or rhabdomyolysis traditionally
caused by statin treatment alone [9,81,82]. However, at
present, the side effects of the combined therapy are not
well described, and it is unclear how effective these are for
impacting the inflammatory profile [73,74,83].
Oxidant Stress, Inflammation and Pharmaceutical
Therapies
While lowering overall cholesterol levels can lead to a
decrease in vascular oxidative stress and thereby
improve endothelial function, some groups have found
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tins [84]. When evaluated to examine NO in a biologi-
cally active form, cholesterol lowering drugs were shown
to increase the efficiency of the NOS system, while
simultaneously showing an inactivation of oxygen radi-
cals within the system [85]. These drugs may not act
directly upon the radicals, but instead act to reduce oxi-
dant stress by decreasing substrate availability for these
radicals to act upon or by increasing antioxidant enzy-
matic activities, such as SOD [86]. Statins have found to
act upon the p21 Rac protein interrupting the NOX
subunit assembly working directly to inhibit the produc-
tion mechanism of superoxides through disruption of
the NOX enzyme [87]. Some studies have shown posi-
tive results with respect to lipid peroxidation, including
the increase of an antioxidant effect leading to a
decrease in ox-LDL with combination ezetimibe/statin
treatment [88].
Pharmaceutical treatments have been shown to influ-
ence inflammation through the decrease of systemic
markers of inflammation and to increase the stability of
existing plaques, thereby reducing the risk for thrombo-
sis. Some groups are considering treating LDL as means
to managing inflammation and preventing atherosclero-
tic lesions with mixed reviews and results [89,90].
CRP has been commonly used as a marker of inflam-
mation in a clinical setting since it is associated with
low-grade cardiovascular inflammation. Statin drugs
have been shown to decrease CRP in numerous human
studies, including JUPITER, ENHANCE, CARE, and
PRINCE, regardless of their lipid lowering effects [91].
Additional studies have shown an interference with the
inflammatory process, impacting the expression of inter-
leukins, adhesion molecules, platelet aggregation, and
chemoattractants including IL-1, IL-6, IL-8, NF-B, and
TNF-a culminating in the decrease of CRP [92].
Animal studies have shown atorvastatin to reduce
inflammatory markers such as MCP-1 and the activation
of the nuclear factor NF-B [93]. More recently, as the
pleiotropic effects of these interventions are being evalu-
ated, some studies have found reductions in the adhe-
sion molecules ICAM, VCAM, E-selectin, P-selectin,
and platelet aggregation. These reductions are leading
some to the conclusion that pharmaceutical therapies
may reduce or limit the formation and instability of
atherosclerotic plaques [94].
Hypercholesterolemia and Exercise
The AHA and American College of Sports Medicine
(ACSM) have recently released joint guidelines recom-
mending aerobic and resistance physical activities for
individuals under the age of 65 to maintain health,
reduce risk of chronic disease states, and manage cur-
rent risk factors including hypercholesterolemia [95-97].
Hypercholesterolemia has been shown to impair aerobic
capacity by impairing dilator regulation, thought to be
due to a lack of vascular reactivity stemming from a
reduction in NO bioavailability [98]. However, this
decline in vascular reactivity may also be due to wall
remodeling as seen in the LDLR mouse model of FH or
poor blood flow distribution due to microvessel rarefac-
tion seen in the ApoE mouse model of FCH [56]. These
may lead to a decrease in oxygen transport to working
skeletal muscles during the hyperemic demand of exer-
cise, further reducing aerobic capacity [98].
Few groups examine dose-response relationships
between exercise training and cholesterol adaptations.
Some have suggested that exercise can alter blood lipids
at low training volumes, although effects may not be sig-
nificant until certain caloric thresholds are met. Exercise
training has rarely been shown to have a direct effect on
total cholesterol or LDL levels; however, significant
increases in HDL and decreases in triglycerides have
been identified [99]. This may be a function of activity
intensity, as a 1200 - 2200 kcal/week exercise program
performed at moderate intensities, has been shown to
reduce total and LDL cholesterol levels [99].
A number of moderate-intensity exercise programs
have shown improvements to systemic aerobic capacity,
effectively reversing early stage hypercholesterolemic
changes within the vasculature, including improved vas-
cular reactivity, NO bioavailability and eNOS activity
[40,100]. These increases in NO bioavailability in
humans and animal models of hypercholesterolemia
have been attributed to eNOS expression and produc-
tion of NO, due to a chronic rise in shear stress with
exercise, as opposed to an increase in SOD or reduction
in oxidant stress [101]. Exercise and shear stress have
also been shown to improve mechanisms of endothelial
vasodilation other than NO, such as prostaglandin
release [12]. Exercise has also been shown to ameliorate
increases in inflammatory and oxidative stress markers
during chronic disease state, which would benefit many
low-grade inflammatory conditions [102].
Inflammation, Oxidant Stress and Exercise
In the past, inflammation associated with physical activ-
ity has been described as the reaction to a number of
repeated micro-traumas to the muscle [103]. However,
muscle has recently been identified as an endocrine
organ, possessing the ability to manufacture and release
humoral mediators directly into the system in response
to muscle contraction [104]. This establishes a link
between skeletal muscle activity and anti-inflammatory
effects [105]. The cytokines produced, identified as myo-
kines, include IL-6, IL-8, IL-15, brain-derived neuro-
trophic factor (BDNF), leukemia inhibitory factor (LIF)
FGF21 and follistatin-like-1: each are regulated in some
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[106]. With respect to IL-6, the myokine hypothesis sug-
gests that both type I and type II muscle fibers are cap-
able of producing and releasing IL-6, which may act
locally through AMPK signaling or systemically to
improve hepatic glucose production and lipid metabo-
lism [107].
During acute exercise, there is an immediate increase
in a variety of anti-inflammatory cytokines, such as IL-6,
IL-1ra, sTNFR (soluble TNF-a receptor), and IL-10.
However, pro-inflammatory cytokines TNF-a (tumor
necrosis factor-a) and IL-1 are generally not changed
[108]. Chronic exercise leads to a reduction of systemic
and local markers of inflammation within the vascula-
ture has been well established within the literature
[109]. As exercise persists to a chronic state pro-inflam-
matory markers CRP, TNF-a, IFN-g, MCP-1, IL-6, IL-8,
and MMP-9 have all been shown to decrease from
initial baseline levels; whereas anti-inflammatory mar-
kers IL-10 and TGF-b increase indicating the develop-
ment of a less inflammatory phenotype [110,111]. The
timeline and exact mechanisms by which a chronic
increase in activity will lead to modest improvements in
low-grade inflammation are uncertain [112]. However,
some groups are focusing on the “long-term anti-inflam-
matory effects of exercise” [105,110].
Cellular respiration and metabolism are directly linked
to physical activity and exercise as they are the source
responsible for muscle action. In the presence of oxygen,
aerobic respiration allows for the production of ATP,
where glucose is broken down to pyruvate and enters
the mitochondria for further processing via Kreb’sc y c l e
and oxidation via the electron transport chain. Unfortu-
nately, minor inefficiencies within the mitochondria,
including leaky membranes and limited cofactor avail-
ability, lead to a reduced ATP generation and the excess
buildup of oxidants [113].
In acute exercise alterations to the mitochondrial elec-
tron transport chain is a direct source of oxidant stress
due to the significant amount of oxidative handling
throughout the system [92]. Therefore, any inefficiencies
associated within this system are multiplied as mito-
chondrial requirements increase due to an increase in
activity, specifically during acute exercise when there is
an increase in whole body oxygen consumption thereby
increasing the generation of ROS by active tissues [114].
During the production of these mitochondrial-derived
radicals, there is also an increase of the pro-oxidant
enzymes xanthine oxidase, myeloperoxidase, and NOX
[115]. The upregulation of these enzymes causes an
increase in plasma markers of ROS, such as F2-isopros-
tanes [116]. This increased oxidant stress, while promot-
ing negative cardiovascular effects, has recently been
shown to occur in conjunction with increases in antibo-
dies to ox-LDL and antioxidant enzymes (catalase) after
one week of activity in mice [117]. These changes sug-
gest that after only a week of moderate activity, there is
an initiation to improve hypercholesterolemia, limit the
progression of foam cell development, and increase anti-
oxidant enzyme activity within exercising and sedentary
states. As exercise persists, mitochondrial and antioxi-
dant enzymes also improve; specifically, an increase in
expression of Cu/Zn superoxide dismutase (SOD-1) and
glutathione peroxidase lead to a higher oxidant handling
capacity and contributiont oi m p r o v e df u n c t i o n
[101,118]. As a consequence, there is a decrease in the
plasma markers of oxidative stress F2-isoprostane, mye-
loperoxidase, and malondialdehyde [119]. Exercise train-
ing has also been shown to have a direct positive effect
on the induction of eNOS and ecSOD (endothelial cell
SOD), potent antioxidants. These increases are interde-
pendent, as eNOS
-/- mice seem to be unaffected an
increase in ecSOD [120].
Exercise and increases in NO have also been shown to
induce HO-1 (heme oxygenase-1) expression. HO-1
products have similar anti-oxidant and anti-inflamma-
tory effects, in addition to the inhibition of NF-KB an
oxidant stress sensitive transcription factor [121]. The
inhibition of NF-kB leads to a decrease of the entire
downstream signaling cascade, which could be the link
to many of the NO-mediated anti-inflammatory effects
observed with chronic exercise such as decreases in leu-
kocyte binding, chemotaxis, aggregation of platelets, and
proliferation of smooth muscle cells [122].
Conclusion
Given the severity of hypercholesterolemia as a risk fac-
tor for the progression of negative CVD outcomes, the
pathways of effective interventional strategies to manage
cholesterol levels, improve vascular reactivity, and
restore NO bioavailability warrant continued investment.
Pharmaceutical therapies have presented a variety of
vasculoprotective effects which are not fully understood,
but involve a complex interaction between vascular sig-
naling mechanisms, oxidant stress and chronic inflam-
mation. Additionally, physical activity and exercise have
long been suggested as means to modify CVD and man-
age cholesterol. Current evidence also supports the the-
ory of a long term anti-inflammatory effects through
modifications of the IL-6 and CRP pathways, along with
anti-oxidative effects of increased anti-oxidant enzyme
expression and activity leading to a higher oxidant
handling capacity at rest and during activity. These data
suggest that the pleiotropic effects of exercise and con-
ventional pharmaceutical therapies may be most benefi-
cial when used in combination.
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